Clinical impact of post-progression survival in patients with locally advanced non-small cell lung cancer after chemoradiotherapy

被引:0
|
作者
Imai, Hisao [1 ,2 ]
Kobayashi, Daijiro [3 ]
Kaira, Kyoichi [2 ]
Kawashima, Sayaka [4 ]
Masubuchi, Ken [1 ]
Murata, Masumi [3 ]
Ebara, Takeshi [3 ,5 ]
Kitamoto, Yoshizumi [3 ]
Minato, Koichi [1 ]
机构
[1] Gunma Prefectural Canc Ctr, Div Resp Med, 617-1 Takahayashinishi, Ota, Gunma 3738550, Japan
[2] Saitama Med Univ, Comprehens Canc Ctr, Int Med Ctr, Dept Resp Med, Hidaka, Saitama, Japan
[3] Gunma Prefectural Canc Ctr, Div Radiat Oncol, Ota, Gunma, Japan
[4] Gunma Prefectural Canc Ctr, Div Pharm, Ota, Gunma, Japan
[5] Kyorin Univ, Sch Med, Dept Radiat Oncol, Mitaka, Tokyo, Japan
关键词
chemoradiotherapy; Glasgow prognostic score; locally advanced non-small cell lung cancer; overall survival; post-progression survival; progression-free survival; GLASGOW PROGNOSTIC SCORE; SURROGATE END-POINTS; PHASE-III TRIAL; POSTPROGRESSION SURVIVAL; PERFORMANCE STATUS; TUMOR RESPONSE; CHEMOTHERAPY; THERAPY; METASTASIS; EFFICACY;
D O I
10.2478/raon-2022.0006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. The efficacy of first-line chemoradiotherapy for overall survival (OS) might be confounded by the subsequent treatments in patients with locally advanced non-small cell lung cancer (NSCLC). In this study, we assessed the associations of progression-free survival (PFS) and post-progression survival (PPS) with OS after chemoradiotherapy for locally advanced NSCLC using patient-level data. Patients and methods. Between January 2011 and December 2018, 45 patients with locally advanced NSCLC who had received first-line chemoradiotherapy and in whom recurrence occurred were analysed. The associations of PFS and PPS with OS were analysed at the individual level. Results. Linear regression and Spearman rank correlation analyses revealed that PPS was strongly correlated with OS (r = 0.72, p < 0.05, R 2 = 0.54), whereas PFS was moderately correlated with OS (r = 0.58, p < 0.05, R-2 = 0.34). The Glasgow prognostic score and liver metastases at recurrence were significantly associated with PPS (p < 0.001). Conclusions. The current analysis of individual-level data of patients treated with first-line chemoradiotherapy implied that PPS had a higher impact on OS than PFS in patients with locally advanced NSCLC. Additionally, current perceptions indicate that treatment beyond progression after first-line chemoradiotherapy might strongly affect OS.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Clinical impact of post-progression survival in patients with locally advanced non-small cell lung cancer after chemoradiotherapy
    Imai, Hisao
    Kobayashi, Daijiro
    Kaira, Kyoichi
    Kawashima, Sayaka
    Masubuchi, Ken
    Murata, Masumi
    Ebara, Takeshi
    Kitamoto, Yoshizumi
    Minato, Koichi
    RADIOLOGY AND ONCOLOGY, 2022, 56 (02) : 228 - 237
  • [2] Clinical impact of post-progression survival on overall survival in patients with limited-stage disease small cell lung cancer after first-line chemoradiotherapy
    Kasahara, Norimitsu
    Imai, Hisao
    Kaira, Kyoichi
    Mori, Keita
    Wakuda, Kazushige
    Ono, Akira
    Taira, Tetsuhiko
    Kenmotsu, Hirotsugu
    Harada, Hideyuki
    Naito, Tateaki
    Murakami, Haruyasu
    Endo, Masahiro
    Nakajima, Takashi
    Yamada, Masanobu
    Takahashi, Toshiaki
    RADIOLOGY AND ONCOLOGY, 2015, 49 (04) : 409 - 415
  • [3] Clinical impact of post-progression survival on overall survival in elderly patients with extensive disease small-cell lung cancer
    Imai, Hisao
    Mori, Keita
    Watase, Nodoka
    Kazama, Toshifumi
    Fujimoto, Sakae
    Kaira, Kyoichi
    Yamada, Masanobu
    Minato, Koichi
    THORACIC CANCER, 2016, 7 (06) : 655 - 662
  • [4] Individual-level data on the relationships of progression-free survival, post-progression survival and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer
    Imai, H.
    Takahashi, T.
    Mori, K.
    Ono, A.
    Akamatsu, H.
    Shukuya, T.
    Taira, T.
    Kenmotsu, H.
    Naito, T.
    Murakami, H.
    Endo, M.
    Nakajima, T.
    Yamamoto, N.
    NEOPLASMA, 2014, 61 (02) : 233 - 240
  • [5] Clinical significance of post-progression survival in lung cancer
    Imai, Hisao
    Kaira, Kyoichi
    Minato, Koichi
    THORACIC CANCER, 2017, 8 (05) : 379 - 386
  • [6] Post-Progression Survival Influences Overall Survival among Patients with Advanced Non-Small Cell Lung Cancer Undergoing First-Line Pembrolizumab Monotherapy
    Imai, Hisao
    Kishikawa, Takayuki
    Minemura, Hiroyuki
    Yamada, Yutaka
    Ibe, Tatsuya
    Mori, Keita
    Yamaguchi, Ou
    Mouri, Atsuto
    Hamamoto, Yoichiro
    Kanazawa, Kenya
    Kasai, Takashi
    Kaira, Kyoichi
    Kaburagi, Takayuki
    Minato, Koichi
    Kobayashi, Kunihiko
    Kagamu, Hiroshi
    ONCOLOGY, 2021, 99 (09) : 562 - 570
  • [7] Clinical Impact of Post-Progression Survival on Overall Survival in Elderly Patients with Non-Small-Cell Lung Cancer Harboring Sensitive EGFR Mutations Treated with First-Line EGFR Tyrosine Kinase Inhibitors
    Imai, Hisao
    Yamada, Yutaka
    Sugiyama, Tomohide
    Minemura, Hiroyuki
    Kaira, Kyoichi
    Kanazawa, Kenya
    Kasai, Takashi
    Kaburagi, Takayuki
    Minato, Koichi
    CHEMOTHERAPY, 2018, 63 (03) : 181 - 189
  • [8] Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy
    Imai, Hisao
    Mori, Keita
    Ono, Akira
    Akamatsu, Hiroaki
    Taira, Tetsuhiko
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Kaira, Kyoichi
    Murakami, Haruyasu
    Endo, Masahiro
    Nakajima, Takashi
    Takahashi, Toshiaki
    MEDICAL ONCOLOGY, 2014, 31 (08)
  • [9] Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer
    Imai, Hisao
    Mori, Keita
    Wakuda, Kazushige
    Ono, Akira
    Akamatsu, Hiroaki
    Shukuya, Takehito
    Taira, Tetsuhiko
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Kaira, Kyoichi
    Murakami, Haruyasu
    Endo, Masahiro
    Nakajima, Takashi
    Yamamoto, Nobuyuki
    Takahashi, Toshiaki
    ANNALS OF THORACIC MEDICINE, 2015, 10 (01) : 61 - 66
  • [10] Clinical Impact of the Relationship between Post-Progression Survival and Overall Survival in Extensive Disease Small Cell Lung Cancer Patients
    Imai, Hisao
    Mori, Keita
    Watase, Nodoka
    Fujimoto, Sakae
    Kaira, Kyoichi
    Yamada, Masanobu
    Minato, Koichi
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S726 - S727